Ivax Diagnostics Q1 Net Revenues Down
For the first quarter of 2010, the company posted a net loss of $0.95m, or $0.03 per diluted share, compared $0.46m, or $0.02 per diluted share, for the comparable period in 2009. Loss from operations was $0.88m, compared to $0.39m for the comparable period in 2009.
Charles Struby, president and CEO of Ivax Diagnostics, said: “We continued our transition during the first quarter of the year, with some important organizational changes as well as the signing of three collaborative agreements highlighting our initiatives.
“We have more work to do and progress to achieve, and with what we believe to be a strong balance sheet, operational improvements and growth plans in place, we look forward to continuing our efforts to transform our company and reporting on those efforts in the upcoming months.”
Will Ivax further reduce its net loss in Q2?
Have your say and discuss with your peers on the InfoGrok community.
Participate by posting your comments now.